TDAP in Burn Patients (Group 2)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorHenry M. Jackson Foundation for the Advancement of Military Medicine
About this trial
This study is following adult patients with serious burn injuries to better understand how their bodies respond to treatment and recovery. Researchers will collect small amounts of blood and tissue samples, along with information already recorded in the medical record, such as vital signs, lab results, and details of surgeries or complications. The goal is to identify patterns that may help predict who is at higher risk for infections or other problems after a burn injury. This information could lead to new tools, including computer-based models, to improve burn care and outcomes in the future. Participation involves providing samples and allowing researchers to review medical records during the hospital stay and up to one year after discharge.
Eligibility criteria
Qualifiers
Male and female ages 18 years and older (maximum age of 80 years old) with burn injury or related illness requiring surgical care or treatment in a critical care or emergency setting who are being cared for at an SC2i-member clinical care facility (Emory/Grady, USF and USAISR) will be considered for study.
Burn Injury >10% TBSA
Ability to understand the purposes and risks of the study and willingly give written informed consent, or in the case of incapacitated patients, a willing legally authorized representative (LAR) is able to give written informed consent.
Disqualifiers
Any condition that, in the opinion of the attending physician, would place the patient or volunteer subject at undue risk by participating. Specific conditions include but are not limited to anemia prohibitive of phlebotomy, or technical considerations that would prevent acquisition of sufficient tissue for clinical use.
Pregnant patients
Minors < 18 years of age
Prisoners
Trial design
Treatments tested in this trial
- Observational Cohort (No Intervention)
Treatment groups
80 Participants
are divided into 1 treatment groupSponsors and collaborators
Henry M. Jackson Foundation for the Advancement of Military Medicine
Lead sponsor
United States Department of Defense
Collaborator
Emory University
Collaborator
United States Army Institute of Surgical Research
Collaborator
University of South Florida
Collaborator
Uniformed Services University of the Health Sciences
Collaborator
Source ClinicalTrials.gov